Skip to content

MRI-Guided Laser Induced Thermal Therapy

MRI-Guided Laser-Induced Thermal Therapy for Cytoreduction of Inoperable Grade III/IV GLiomas Prior to Chemotherapy and Radiation

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01515085
Acronym
LITT
Enrollment
1
Registered
2012-01-23
Start date
2011-08-31
Completion date
2012-06-30
Last updated
2014-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant Glioma

Brief summary

Does MR-guided laser interstitial thermal therapy (MRgLITT) prior to chemotherapy and/or radiation give patients a beneficial increase in overall survival? Laser induced thermal therapy (LITT) is a minimally invasive procedure for destroying tissue through generation of heat.

Detailed description

Laser induced thermal therapy (LITT) is a procedure for destroying tissue through generation of heat. When used in conjunction with fiberoptic applicators, it offers an excellent means of minimally invasive surgery. As opposed to other thermal techniques like radio-frequency (RF) ablation, or cryo-ablation, LITT may be significantly faster and may exhibit sharper boundary of the thermal ablation zone. More importantly, LITT is highly compatible with MR imaging and when coupled with MR thermal imaging (MRTI) guidance, precise monitoring of the thermal ablation zone in order to avoid eloquent or critical structures is possible. In this study, we propose to evaluate MR-thermal image guided laser interstitial therapy for the treatment of inoperable brain tumors as upfront therapy prior to initiation of chemotherapy and radiation. MR-thermal imaging (MRTI) will be used to provide information on thermal dose delivered to the target and be used to control laser delivery to prevent damage to critical structures.

Interventions

residual gliomas either after debulking or biopsy evaluated for intervention with laser ablation prior to onset of adjuvant therapy

Sponsors

Rutgers Cancer Institute of New Jersey
CollaboratorOTHER
Rutgers, The State University of New Jersey
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Subjects that have/will undergo MRgLITT for inoperable brain tumor. * Tumor size \< 3cm in transverse diameter for each planned applicator placement. * Tumor size \< 4 cm in largest dimension. * Lesion(s) are clearly defined on pre-therapy contrast enhanced MRI scans as determined by the treating surgeon. * Karnofsky Performance Scale score \> 70. * ECOG performance status of 2 or better. * Biopsy proven histologic diagnosis of malignant glioma.

Exclusion criteria

* Patients with co-existing medical conditions with life expectancy \< 1 year. * Patients having received pre-ablation chemotherapy and/or radiation to lesion.

Design outcomes

Primary

MeasureTime frame
Progression free survivalthree years

Secondary

MeasureTime frame
Overall survivalthree years

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026